News - normaxbiomed.com

NewsPeter A. Jensen2022-10-24T09:50:51+00:00

Normax Press Room

Normax partners with Medical Technologies Innovation Facility at Nottingham Trent University to offer access to BioXp system by Telesis Bio

The collaboration agreement with Normax Biomed Ltd, will enable The Medical Technologies Innovation Facility at Nottingham Trent University to accelerate the development and discovery of new mRNA vaccines and gene therapies. 24 January 2023 – Normax Biomed Limited (“Normax”) has launched a partnership with the Medical Technologies Innovation Facility (MTIF) at Nottingham Trent University (NTU) to offer access to its BioXPTM system by Telesis Bio Inc. and to innovate in RNA technology. The BioXPTM is the world’s first commercially [...]

January 24, 2023|

Normax to invest €30,000,000 in first Vax Factory for mRNA vaccine manufacturing in Dublin, Ireland

Normax is building a path for rapid growth of its global headquarters in Dublin, Ireland. With €300 million capital commitment from a cornerstone investor for research, development and manufacturing of mRNA vaccines DUBLIN, Ireland. 19 November 2022 - Normax plans to invest €30,000,000 in its first Vax Factory in Dublin after recently securing a €300 million pre-IPO capital commitment to help drive down the cost of vaccines, save more lives and support long-term sustainable pandemic preparedness. Aiming to boost [...]

November 19, 2022|

Normax secures €300,000,000 capital commitment from Global Emerging Markets (GEM) for research and development and manufacturing of mRNA Vaccines for transformative global social impact

Normax plans to use capital finance to scale mRNA Vaccine Research and Development with Vax Factory Manufacturing for Transformative Social Impact on Infectious Diseases, Rare Diseases, Cancers and Pandemic Preparedness July 11, 2022, 12:00 PM Greenwich Mean Time (GMT) - PRESS RELEASE. NOT AN OFFER. SEE DISCLAIMER. DUBLIN, Ireland -- The mRNA vaccine technology company Normax Biomed Limited (“Normax”), today announced a €300 Million investment commitment from GEM Global Yield LLC SCS (“GEM”), the $3.4 Billion, Luxembourg based, private [...]

July 11, 2022|

Media Contact

Berkeley Communications
+44 118 909 0909
normax@berkeleypr.com

Download Press Kit

Berkeley PR

Normax In-the-News

Forward Looking Statements. No Offer or Solicitation. Professional Investors Only.Peter A. Jensen2023-02-03T11:00:00+00:00

Forward Looking Statements. No Offer or Solicitation. Professional Investors Only.

This website includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “will,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include statements about our beliefs and expectations and the estimated financial information and other projections contained herein. Such forward-looking statements with respect to revenues, earnings, performance, strategies, prospects and other aspects of the businesses of Normax Biomed Ltd. are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those expressed or implied by such forward-looking statements. Please refer to the final prospectus of Normax Biomed Limited under “Risk Factors” therein, and other documents filed or to be filed with the London Stock Exchange and the Swiss Stock Exchange (SIX) by Normax Biomed Ltd. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Normax Biomed Ltd. undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

The information on this website shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction. The information on this website shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the listing requirements of the London Stock Exchange and the Swiss Stock Exchange (SIX).

This website is directed only at, and provides information about products and services only available to, those who are Professional Clients or Eligible Counterparties as defined by the Financial Conduct Authority. The definitions can be found on the FCA website at www.fca.org.uk. This website is not intended to be accessed by any persons or entities domiciled in any jurisdiction where being treated as the types of clients stated would be contrary to local law.

Normax AbstractPeter A. Jensen2022-08-31T11:50:39+00:00

Normax Abstract

Normax Biomed Ltd (Normax) is based in Cork, Ireland, and London, England. Normax is in the business of mRNA vaccine Research, Development and Manufacturing. Normax has secured a €300,000,000 capital commitment from a $3.4Bn cornerstone institutional investor for development of mRNA Vaccines and Vax Factory Manufacturing for Transformative Social Impact on Infectious Disease and Pandemic Preparedness. Normax plans to drive down the cost of mRNA Vaccines to save more lives and to deliver sustainable returns for impact investors. Normax plans to deliver safe and effective mRNA vaccines at large scale for about $4 dollars per dose. Normax mRNA vaccine products in development include: (1) mRNA Vax Factory, (2) Universal Coronavirus mRNA Vaccine, (3) Tuberculosis mRNA Vaccine, (4) HIV mRNA Vaccine, (5) Malaria mRNA Vaccine, and (6) Disease-X mRNA Vaccine (e.g. within 100 days). Normax mission is to deliver competitive financial performance with transformative social impact. NOT AN OFFER TO INVEST.